In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection ... lead from rival Eli Lilly (LLY.N), opens new tab in the competitive obesity drug market.

Each of these GLP-1 treatments are developed by either Novo Nordisk or Eli Lilly. Where to invest ... what could happen with approved weight loss drugs when you consider competitors and Holz's ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Right now, Novo Nordisk and Eli Lilly are the biggest players in town ... out considering what could happen with approved weight loss drugs when you consider competitors and Holz's proposed ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...